Abstract CT215: A Phase 1 Study of INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis (INCB 57643-103)
Authors: Vachhani Pankit , Lihou Christine , Zhou Gongfu , Zheng Fred 
Published: July 2021

Background: Many neoplasms including myelofibrosis (MF) are associated with activation of transcription factors that regulate oncogenic processes. These may respond to inhibition of bromodomain and extra-terminal domain (BET) protein. In the first-in-human study INCB 57643-101, the BET inhibitor INCB057643, was generally safe and tolerable as monotherapy, and demonstrated preliminary efficacy in patients (pts) with MF as monotherapy or combined with the JAK inhibitor, ruxolitinib (Falchook G, et al. Clin Cancer Res. 2020). This phase 1, open-label, two-part dose confirmation and expansion study further evaluates the safety and tolerability of INCB057643 monotherapy in pts with relapsed/refractory MF (INCB 57643-103; NCT04279847). Methods: Eligible pts must be ≥18 y with histologically confirmed primary or secondary MF (post-polycythemia vera, post-essential thrombocythemia), have received ≥1 prior therapy including ruxolitinib, have no known clinically beneficial therapy available, have intermediate-2/high risk disease by Dynamic International Prognostic Scoring System, have ECOG PS 0-2, life expectancy ≥24 wks, and willing to provide a bone marrow biopsy and/or aspirate at baseline (or archival sample obtained after most recent therapy). Exclusion criteria include prior BET inhibitor or anticancer treatment within specified intervals before first dose; concurrent anticancer therapy; allogeneic hematopoietic stem cell transplant (allo-HSCT) ≤6 months before enrollment; active graft versus host disease or immunosuppressive therapy after allo-HSCT ≤2 wks before first-dose; significant and uncontrolled disease (eg, gastrointestinal, cardiovascular); history of bleeding disorders, high risk of bleeding, or abnormal hematologic, hepatic, renal, coagulation, or metabolic laboratory values. In part 1, ≤6 pts will receive oral INCB057643 4 mg once-daily (QD) continuously. Doses will be deemed tolerable if ≤2 pts experience dose-limiting toxicities (DLTs) and ≤2 pts discontinue due to treatment-related adverse events (TRAEs) during the DLT evaluation period. Part 2 will further characterize safety and tolerability as well as evaluate preliminary efficacy of INCB057643 in ≤9 pts. The starting dose will be 4 mg QD if tolerated in Part 1, and 2 mg QD if not. Treatment may continue if clinically beneficial and discontinuation criteria are not met. The primary objective is to determine safety and tolerability of INCB057643 monotherapy. Secondary objectives are to evaluate anemia response by International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet Consensus Report (ELN), transfusion dependence, spleen volume, rate and duration of spleen response by IWG-MRT and ELN, and impact on quality of life. Pts will be assessed every 3 cycles and will receive follow-up for safety for 30-35 days after last dose.

Citation Format: Pankit Vachhani, Christine Lihou, Gongfu Zhou, Fred Zheng. A Phase 1 Study of INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis (INCB 57643-103) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr CT215.